Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
MechanismIonising radiation emitters |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase I Study to Evaluate the Safety, Tolerance and Efficacy of NRT6008 Injection in Unresectable Locally Advanced Pancreatic Cancer (LAPC)
This is a single arm, open label, multi-center phase I study, including phase Ia dose escalation and phase Ib dose expansion. Safety review committee (SRC) will be formed to monitor safety and efficacy data through the study. And the independent review committee (IRC) will be formed to monitor efficacy data through the study.
Study on the Safety and Effectiveness of NRT6003 Injection in Patients With Unresectable Hepatocellular Carcinoma (HCC)
The goal of this clinical trial is to evaluate the safety and efficacy of NRT6003 Injection in patients with unresectable HCC.
评价 NRT6003 注射液在不可手术切除的肝细胞癌患者中的安全性及有效性的临床研究
[Translation] A clinical study evaluating the safety and efficacy of NRT6003 injection in patients with unresectable hepatocellular carcinoma
评价NRT6003注射液在不可手术切除的肝细胞癌患者中的安全性及有效性;探索 NRT6003注射液给药后钇 [90Y]炭微球在人体的分布特征。
[Translation] To evaluate the safety and efficacy of NRT6003 injection in patients with unresectable hepatocellular carcinoma; to explore the distribution characteristics of yttrium [90Y] carbon microspheres in the human body after administration of NRT6003 injection.
100 Clinical Results associated with Chengdu New Radiomedicine Technology Co., Ltd.
0 Patents (Medical) associated with Chengdu New Radiomedicine Technology Co., Ltd.
100 Deals associated with Chengdu New Radiomedicine Technology Co., Ltd.
100 Translational Medicine associated with Chengdu New Radiomedicine Technology Co., Ltd.